Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients

被引：0
|
作者：
Iborra, M. [1 ,2 ]
Maroto, N. [3 ]
Navarro-Cortes, P. [4 ]
Beltran, B. [1 ,2 ]
Bosca-Watts, M. [4 ]
Ferrer, I. [3 ]
Garcia-Morales, N. [1 ,2 ]
Saez-Gonzalez, E. [1 ,2 ]
Hinojosa, J. [3 ]
Minguez, M. [4 ]
Nos, P. [1 ,2 ]
机构：
[1] La Fe Univ & Polytech Hosp, Valencia, Spain
[2] CIBER EHD, Dept Gastroenterol, Valencia, Spain
[3] Hosp Manises, Dept Gastroenterol, Manises, Spain
[4] Univ Clin Hosp Valencia, Dept Gastroenterol & Hepatol, Valencia, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P714
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 50 条
  • [1] Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
    Iborra, Marisa
    Beltran, Belen
    Maroto, Nuria
    Navarro-Cortes, Pablo
    Bosca-Watts, Maia
    Ferrer-Bradley, Isabel
    Garcia-Morales, Natalia
    Saez-Gonzalez, Esteban
    Hinojosa, Joaquin
    Minguez, Miguel
    Nos, Pilar
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (09): : 535 - 543
  • [2] Course of Crohn's Disease (CD) in Thiopurine-Intolerant Patients
    Attali, Julia
    Seksik, Philippe
    Bourrier, Anne
    Nion-Larmurier, Isabelle
    Beaugerie, Laurent
    Sokol, Harry
    Cosnes, Jacques
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S240 - S240
  • [3] Outcome of thiopurine-intolerant patients with Crohn's disease (CD)
    Attali, J.
    Seksik, P.
    Bourrier, A.
    Nion-Larmurier, I.
    Beaugerie, L.
    Sokol, H.
    Cosnes, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S133 - S133
  • [4] Patients with inflammatory bowel disease who are intolerant to thiopurine treatment
    Karling, P.
    Gensmyr-Singer, H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1594 - I1594
  • [5] Effect of vedolizumab and ustekinumab on articular manifestations in patients with inflammatory bowel disease refractory or intolerant to anti-TNF therapy: An observational prospective study
    Britschu, O.
    Meyer, A.
    Gottenberg, J. E.
    Reimund, J. M.
    Caron, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S472 - S473
  • [6] Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease
    Crowell, K. T.
    Tinsley, A.
    Williams, E. D.
    Coates, M. D.
    Bobb, A.
    Koltun, W. A.
    Messaris, E.
    [J]. COLORECTAL DISEASE, 2018, 20 (10) : 905 - 912
  • [7] Distribution of IgG4 Cells in Medically Refractory Patients With Inflammatory Bowel Disease
    Hartman, Douglas J.
    Binion, David G.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S789 - S789
  • [8] Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease
    Zakerska-Banaszak, Oliwia
    Lykowska-Szuber, Liliana
    Walczak, Michal
    Zuraszek, Joanna
    Zielinska, Aleksandra
    Skrzypczak-Zielinska, Marzena
    [J]. TOXICS, 2022, 10 (04)
  • [9] SAFETY OF VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [10] Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
    Christensen, Britt
    Gibson, Peter R.
    Micic, Dejan
    Colman, Ruben J.
    Goeppinger, Sarah R.
    Kassim, Olufemi
    Yarur, Andres
    Weber, Christopher R.
    Cohen, Russell D.
    Rubin, David T.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (03) : 486 - 493
12345